BioCentury
ARTICLE | Company News

Alexion refocusing on complement cascade

July 28, 2017 1:21 AM UTC

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) restructured its pipeline to focus on its core complement inhibitor franchise and its approved rare disease products, dropping early stage rare disease partnerships with Moderna Therapeutics Inc. (Cambridge, Mass.), Blueprint Medicines Corp. (NASDAQ:BPMC) and Arbutus Biopharma Corp. (NASDAQ:ABUS).

Alexion’s shares gained $2.85 to $133.92 on Thursday, when it also announced 2Q17 earnings that beat the Street and raised its guidance for 2017...

BCIQ Company Profiles

Alexion Pharmaceuticals Inc.